OpenLB
Open Library of Bioscience
Advanced Search
International journal of molecular sciences
Sep 09, 2009;10 (9): 3951-3970.

Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance?

Lars Steinstraesser, Ursula M Kraneburg, Tobias Hirsch, Marco Kesting, Hans-Ulrich Steinau, Frank Jacobsen, Sammy Al-Benna
Author Information
  1. Lars Steinstraesser: Department of Plastic and Reconstructive Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany.
  2. Ursula M Kraneburg: Department of Plastic and Reconstructive Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany.
  3. Tobias Hirsch: Department of Plastic and Reconstructive Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany.
  4. Marco Kesting: Department of Oral and Maxillofacial Surgery, Technische Universität München, Ismaninger Str. 22, München, Germany.
  5. Hans-Ulrich Steinau: Department of Plastic and Reconstructive Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany.
  6. Frank Jacobsen: Department of Plastic and Reconstructive Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany.
  7. Sammy Al-Benna: Department of Plastic and Reconstructive Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany.
PMID: 19865528 DOI: 10.3390/ijms10093951

Abstract

Host defense peptides can modulate the innate immune response and boost infection-resolving immunity, while dampening potentially harmful pro-inflammatory (septic) responses. Both antimicrobial and/or immunomodulatory activities are an integral part of the process of innate immunity, which itself has many of the hallmarks of successful anti-infective therapies, namely rapid action and broad-spectrum antimicrobial activities. This gives these peptides the potential to become an entirely new therapeutic approach against bacterial infections. This review details the role and activities of these peptides, and examines their applicability as development candidates for use against bacterial infections.

Keywords

antimicrobial peptides bacterial infection host defense peptides inflammation innate immunity sepsis

References

  1. FASEB J. 2004 Aug;18(11):1306-8 [PMID: 15208269]
  2. Antimicrob Agents Chemother. 2006 May;50(5):1672-9 [PMID: 16641434]
  3. Burns. 2004 Nov;30(7):619-27 [PMID: 15475133]
  4. Nucleic Acids Res. 2004 Jan 1;32(Database issue):D586-9 [PMID: 14681487]
  5. J Immunol Methods. 1991 Aug 9;141(2):149-55 [PMID: 1880422]
  6. Ann Plast Surg. 2006 Jan;56(1):93-8 [PMID: 16374104]
  7. Int Immunol. 2000 May;12(5):691-700 [PMID: 10784615]
  8. J Invest Dermatol. 2003 Mar;120(3):379-89 [PMID: 12603850]
  9. Curr Protein Pept Sci. 2007 Oct;8(5):506-20 [PMID: 17979765]
  10. Annu Rev Immunol. 2004;22:181-215 [PMID: 15032578]
  11. J Immunol. 2005 Aug 1;175(3):1776-84 [PMID: 16034119]
  12. J Proteome Res. 2004 May-Jun;3(3):410-6 [PMID: 15253421]
  13. Retrovirology. 2005 Jan 18;2:2 [PMID: 15656908]
  14. J Immunol. 2004 Nov 1;173(9):5398-405 [PMID: 15494486]
  15. Gene Ther. 2005 Oct;12(20):1494-502 [PMID: 15973442]
  16. Cell Mol Life Sci. 2003 Apr;60(4):711-20 [PMID: 12785718]
  17. Annu Rev Immunol. 1995;13:61-92 [PMID: 7612236]
  18. J Immunol. 2004 Jan 15;172(2):1169-76 [PMID: 14707093]
  19. J Invest Dermatol. 2004 Sep;123(3):522-9 [PMID: 15304092]
  20. Immunology. 2002 May;106(1):20-6 [PMID: 11972628]
  21. Nature. 2003 Apr 3;422(6931):522-6 [PMID: 12660734]
  22. FEMS Microbiol Lett. 2002 Jan 10;206(2):143-9 [PMID: 11814654]
  23. J Infect Dis. 1985 Jun;151(6):1012-8 [PMID: 3889171]
  24. Biopolymers. 2006;84(5):435-58 [PMID: 16736494]
  25. J Immunol. 2002 Oct 1;169(7):3883-91 [PMID: 12244186]
  26. Physiol Genomics. 2004 Dec 15;20(1):1-11 [PMID: 15494476]
  27. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1829-33 [PMID: 9465102]
  28. Antimicrob Agents Chemother. 2006 Apr;50(4):1480-8 [PMID: 16569868]
  29. Nat Med. 2006 Jun;12(6):636-41 [PMID: 16751768]
  30. Lung Cancer. 2008 Jan;59(1):12-23 [PMID: 17764778]
  31. Expert Opin Pharmacother. 2006 Apr;7(6):653-63 [PMID: 16556083]
  32. Antimicrob Agents Chemother. 2006 Nov;50(11):3833-8 [PMID: 16940063]
  33. Mol Med. 2008 Jul-Aug;14(7-8):528-37 [PMID: 18385817]
  34. Acta Anaesthesiol Scand. 2003 Feb;47(2):213-20 [PMID: 12631052]
  35. Trends Immunol. 2002 Jun;23(6):291-6 [PMID: 12072367]
  36. Biochim Biophys Acta. 2002 Feb 1;1558(2):171-86 [PMID: 11779567]
  37. Can Commun Dis Rep. 2005 Feb 1;31(3):33-40 [PMID: 15693179]
  38. Eur J Haematol. 1990 Jan;44(1):1-8 [PMID: 2407547]
  39. J Antimicrob Chemother. 2007 Mar;59(3):493-8 [PMID: 17289767]
  40. J Trauma. 2005 Apr;58(4):867-74 [PMID: 15824673]
  41. Protein Pept Lett. 2008;15(3):238-43 [PMID: 18336350]
  42. Toxicol Sci. 2008 Nov;106(1):74-82 [PMID: 18511430]
  43. J Clin Invest. 1989 Aug;84(2):553-61 [PMID: 2668334]
  44. Nucleic Acids Res. 2009 Jan;37(Database issue):D933-7 [PMID: 18957441]
  45. J Immunol. 2000 Jan 15;164(2):549-53 [PMID: 10623792]
  46. Eur J Clin Microbiol Infect Dis. 2001 Nov;20(11):804-7 [PMID: 11783697]
  47. Comb Chem High Throughput Screen. 2005 May;8(3):241-56 [PMID: 15892626]
  48. Infect Disord Drug Targets. 2008 Sep;8(3):135-43 [PMID: 18782030]
  49. N Engl J Med. 2006 Oct 19;355(16):1699-713 [PMID: 17050894]
  50. Br J Surg. 2001 Jan;88(1):22-30 [PMID: 11136305]
  51. Biopolymers. 2000;55(1):4-30 [PMID: 10931439]
  52. Curr Protein Pept Sci. 2005 Feb;6(1):77-84 [PMID: 15638770]
  53. J Immunol. 2003 Jun 1;170(11):5583-9 [PMID: 12759437]
  54. Expert Rev Anti Infect Ther. 2007 Dec;5(6):951-9 [PMID: 18039080]
  55. Lancet. 1968 Oct 5;2(7571):741-4 [PMID: 4175546]
  56. Curr Issues Mol Biol. 2005 Jul;7(2):179-96 [PMID: 16053249]
  57. Biopolymers. 1998;47(6):415-33 [PMID: 10333735]
  58. Nat Rev Microbiol. 2004 Jun;2(6):497-504 [PMID: 15152205]
  59. Science. 1999 Oct 15;286(5439):525-8 [PMID: 10521347]
  60. Curr Pharm Des. 2004;10(23):2891-905 [PMID: 15379675]
  61. Curr Drug Targets. 2007 Apr;8(4):493-500 [PMID: 17430119]
  62. Med Mal Infect. 2007 Apr;37(4):194-9 [PMID: 17306486]
  63. FASEB J. 2007 Apr;21(4):1107-16 [PMID: 17215486]
  64. J Immunol. 2004 Jan 15;172(2):1146-56 [PMID: 14707090]
  65. J Pept Sci. 2005 Nov;11(11):677-87 [PMID: 16103989]
  66. Anesthesiology. 2007 Sep;107(3):437-41 [PMID: 17721246]
  67. J Bacteriol. 2005 Aug;187(15):5387-96 [PMID: 16030233]
  68. J Biol Chem. 2004 Nov 19;279(47):48671-9 [PMID: 15317821]
  69. J Immunol. 2005 Apr 1;174(7):4271-8 [PMID: 15778390]
  70. Antimicrob Agents Chemother. 2005 Jan;49(1):470-2 [PMID: 15616340]
  71. J Biol Chem. 2004 Oct 15;279(42):44188-96 [PMID: 15297466]
  72. Burns. 2008 Feb;34(1):32-40 [PMID: 17714876]
  73. J Immunol. 2001 Sep 15;167(6):3329-38 [PMID: 11544322]
  74. Biophys J. 2000 Oct;79(4):2002-9 [PMID: 11023904]
  75. Mol Immunol. 2006 Mar;43(9):1485-9 [PMID: 16253330]
  76. Nat Immunol. 2005 Jun;6(6):551-7 [PMID: 15908936]
  77. J Biol Chem. 2003 May 9;278(19):16561-6 [PMID: 12621031]
  78. Mol Immunol. 2009 Mar;46(6):1140-8 [PMID: 19118900]
  79. Infect Immun. 1999 Nov;67(11):6084-9 [PMID: 10531270]
  80. Curr Clin Top Infect Dis. 2002;22:1-23 [PMID: 12520644]
  81. J Clin Invest. 2003 Jun;111(11):1665-72 [PMID: 12782669]
  82. J Immunol. 2005 Jun 15;174(12):8003-10 [PMID: 15944307]
  83. J Immunol. 2004 Apr 1;172(7):4637-45 [PMID: 15034083]
  84. FEBS Lett. 1994 Dec 19;356(2-3):169-73 [PMID: 7805831]
  85. Bioinformatics. 2007 May 1;23(9):1148-55 [PMID: 17341497]
  86. Pharmacogenomics. 2004 Jun;5(4):361-79 [PMID: 15165173]
  87. Cell. 1996 Sep 20;86(6):973-83 [PMID: 8808632]
  88. Am J Pathol. 2007 May;170(5):1435-44 [PMID: 17456750]
  89. Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8856-61 [PMID: 10922046]
  90. Biol Chem. 2001 Apr;382(4):597-619 [PMID: 11405223]
  91. J Biol Chem. 1998 Feb 6;273(6):3718-24 [PMID: 9452503]
  92. Br J Dermatol. 2009 Feb;160(2):243-9 [PMID: 19014393]
  93. Trends Microbiol. 2002 Apr;10(4):179-86 [PMID: 11912025]
  94. Mol Med. 2006 Sep-Oct;12(9-10):199-207 [PMID: 17225867]
  95. Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L842-8 [PMID: 15964896]
  96. Infect Immun. 1995 Apr;63(4):1291-7 [PMID: 7890387]
  97. Curr Opin Immunol. 2006 Feb;18(1):24-30 [PMID: 16337365]
  98. Biochem J. 1999 Aug 1;341 ( Pt 3):501-13 [PMID: 10417311]
  99. J Lab Clin Med. 1993 Aug;122(2):202-7 [PMID: 8340706]
  100. Infect Immun. 2002 Jun;70(6):3053-60 [PMID: 12010997]
  101. Biochim Biophys Acta. 1999 Dec 15;1462(1-2):55-70 [PMID: 10590302]
  102. Can J Infect Dis Med Microbiol. 2007 Jan;18(1):27-34 [PMID: 18923684]
  103. Antimicrob Agents Chemother. 2006 Sep;50(9):2983-9 [PMID: 16940092]
  104. Curr Drug Targets Infect Disord. 2002 Mar;2(1):79-83 [PMID: 12462155]
  105. FASEB J. 2006 Jan;20(1):35-42 [PMID: 16394265]
  106. J Endotoxin Res. 2005;11(4):230-6 [PMID: 16176660]
  107. JAMA. 1999 Jan 6;281(1):61-6 [PMID: 9892452]
  108. Crit Rev Immunol. 2000;20(5):407-31 [PMID: 11145218]
  109. Nat Biotechnol. 2006 Dec;24(12):1551-7 [PMID: 17160061]
  110. Lancet Infect Dis. 2001 Oct;1(3):156-64 [PMID: 11871492]
  111. Antimicrob Agents Chemother. 2004 Dec;48(12):4673-9 [PMID: 15561843]
  112. Ann Surg. 2004 Feb;239(2):251-6 [PMID: 14745334]
  113. J Leukoc Biol. 2005 Apr;77(4):451-9 [PMID: 15569695]
  114. Trends Immunol. 2002 Jun;23(6):283-4 [PMID: 12072365]
  115. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8880-5 [PMID: 12840147]
  116. Lancet. 1997 Feb 8;349(9049):418-22 [PMID: 9033483]
  117. J Cell Physiol. 1993 May;155(2):408-13 [PMID: 8482733]
  118. Lancet. 2000 Sep 16;356(9234):961-7 [PMID: 11041396]
  119. Nature. 2002 Jan 24;415(6870):389-95 [PMID: 11807545]
  120. J Immunol. 1999 Jul 15;163(2):947-53 [PMID: 10395691]
  121. Am J Respir Cell Mol Biol. 1991 Aug;5(2):101-6 [PMID: 1716445]
  122. Pediatr Surg Int. 2005 Jan;21(1):20-4 [PMID: 15645239]
  123. Drugs. 2003;63(4):389-406 [PMID: 12558461]
  124. J Immunol. 2006 Feb 15;176(4):2455-64 [PMID: 16456005]
  125. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5610-4 [PMID: 2501794]
  126. Int J Cancer. 2008 Mar 1;122(5):1030-9 [PMID: 17960624]
  127. Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R245-54 [PMID: 15358731]
  128. J Bacteriol. 2000 Jul;182(14):4077-86 [PMID: 10869088]
  129. Biochim Biophys Acta. 1999 Dec 15;1462(1-2):1-10 [PMID: 10590299]
  130. Microbiologia. 1996 Mar;12(1):9-16 [PMID: 9019139]
  131. Lancet. 1948 Oct 23;2(6530):641-4 [PMID: 18890505]
  132. Antimicrob Agents Chemother. 2002 Jun;46(6):1837-44 [PMID: 12019098]

MeSH Term

Animals
Anti-Bacterial Agents
Antimicrobial Cationic Peptides
Bacteria
Bacterial Infections
Drug Resistance, Bacterial
Host-Pathogen Interactions
Humans
Immunity, Innate

Chemicals

Anti-Bacterial Agents
Antimicrobial Cationic Peptides
Journal Article Review
Article has an altmetric score of 6

Word Cloud

Created with Highcharts 10.0.0peptidesinnatedefenseimmunityactivitiesbacterialHostimmuneantimicrobialinfectionscanmodulateresponseboostinfection-resolvingdampeningpotentiallyharmfulpro-inflammatorysepticresponsesand/orimmunomodulatoryintegralpartprocessmanyhallmarkssuccessfulanti-infectivetherapiesnamelyrapidactionbroad-spectrumgivespotentialbecomeentirelynewtherapeuticapproachreviewdetailsroleexaminesapplicabilitydevelopmentcandidatesuseeffectormoleculesresponse:sledgehammerdrugresistance?antimicrobialinfectionhostinflammationsepsis

Similar Articles

Cited By (40)